RPID RAPID MICRO BIOSYSTEMS, INC.

CIK 0001380106 46 ready 8-Ks latest May 19, 2026, 5:13 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 46

Latest filing May 28, 2026, 4:14 PM ET

Top materiality 0.85

Event mix earnings ×24 · other_material ×9 · leadership ×5

Sentiment 18 pos · 7 neg · 21 neu

Latest earnings ▼ miss 2025-FY

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for RPID

Highest-materiality recent filing

Rapid Micro Biosystems Q2 revenue $3.9M; lowers FY22 outlook to ≥$17M, cuts 20% workforce

August 12, 2022, 7:59 PM ET earnings materiality 0.85 negative item 1.01 item 2.02 item 2.05 item 3.03 item 5.02 item 5.03 item 7.01 item 9.01 ◈ executive_change

Q2 commercial revenue $3.9M vs $5.7M YoY; net loss $13.1M ($0.31 loss per share).
Full-year 2022 revenue guidance reduced to at least $17.0M (from prior higher outlook); expects 3-5 system placements in H2.

Read filing →

May 19, 2026, 5:13 PM ET other material materiality 0.70 neutral item 1.01 item 9.01

RPID raises ~$9M in underwritten common stock and warrant offering; insiders add $140K

Underwritten offering of 3.58M units (share + two warrants) at $1.955/unit; net proceeds ~$8.9M.
May 13, 2026, 4:33 PM ET earnings materiality 0.65 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

Rapid Micro Biosystems Q1 revenue up 11% to $8.0M; net loss widens to $14.3M

Total revenue $8.0M (+11% YoY); product revenue $5.6M (+36%).
March 12, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×3

Rapid Micro reports record Q4 revenue $11.3M (+37% YoY); 2026 guidance $37-41M; Samsung Biologics expands Growth Direct

Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).
January 13, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Rapid Micro Biosystems pre-announces record Q4 rev $11.3M (+37% YoY); FY rev $33.6M (+20%)

Q4 2025 total revenue expected ~$11.3M, up ~37% YoY; record multi-system order from Top 20 biopharma customer.
November 7, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Rapid Micro Biosystems Q3 revenue $7.8M (+3% YoY); raises FY guidance after record multi-system order

Q3 2025 revenue $7.8M (+3% YoY); recurring revenue up 32% to $4.8M on record consumables.
August 12, 2025, 7:59 PM ET debt materiality 0.75 positive item 1.01 item 2.02 item 2.03 item 3.02 item 7.01 item 9.01 ◈ Debt Financings

Rapid Micro Biosystems Q2 revenue $7.3M (+10% YoY); enters $45M term loan with Trinity Capital

Q2 2025 revenue $7.3M, up 10% YoY; net loss $11.9M ($0.27/sh) vs $12.6M ($0.29) prior year.
May 9, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Rapid Micro Q1 revenue $7.2M (+28% YoY), gross margin turns positive 6%, net loss narrows to $11.3M

Product revenue $4.1M (+10%), service revenue $3.1M (+64%) driven by record validation activity; 3 new Growth Direct placements.
February 28, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Rapid Micro Biosystems Q4 revenue $8.2M (+30% YoY); gross margin turns positive; announces MilliporeSigma deal

Q4 2024 revenue $8.2M (up 30% vs $6.3M in Q4 2023); product revenue $5.2M (+27%), service revenue $3.0M (+35%).
February 27, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 7.01 item 9.01

Rapid Micro Biosystems signs global distribution deal with Merck KGaA's MilliporeSigma

MilliporeSigma gets co-exclusive global rights to sell Growth Direct systems and consumables in pharma, med device, personal care, cosmetics, food & beverage.
January 14, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Rapid Micro prelim Q4 rev record $8.2M, +30% YoY; Lonza collaboration

Q4 total revenue preliminary ~$8.2M (record), +30% YoY; recurring rev ~$4.2M, +27% YoY.
November 12, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Rapid Micro Biosystems regains Nasdaq minimum bid price compliance

Received Nasdaq letter on Nov 11, 2024 confirming compliance with $1.00 minimum bid price rule.
November 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 5.02 item 9.01 ◈ executive_change

RPID Q3 rev $7.6M (+24%), gross margin turns positive; director resigns

Revenue $7.6M (+24% YoY); seven Growth Direct placements; gross margin positive 8% vs -27% last year.
August 2, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 3.01 item 9.01

Rapid Micro Biosystems Q2 revenue up 32% to $6.6M; Nasdaq transfer due to bid price deficiency

Q2 revenue $6.6M (+32% YoY); net loss $12.6M ($0.29 loss per share) vs $14.0M loss a year ago.
May 3, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Rapid Micro Biosystems Q1 revenue $5.6M (+11% YoY), loss $13.3M; reaffirms FY guidance

Q1 revenue $5.6M (+11% YoY); net loss $13.3M ($0.31/share).
March 1, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Rapid Micro Biosystems Q4 revenue $6.3M (+45% YoY); guides FY2024 revenue ≥$27M

Q4 2023 revenue $6.3M (+45% YoY); placed 6 Growth Direct systems, highest since Q3 2021.
February 2, 2024, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

Rapid Micro Biosystems receives Nasdaq delisting notice for bid price below $1.00

Nasdaq notified RPID on Feb 2, 2024, that bid price closed below $1.00 for 30 consecutive business days (Dec 18, 2023 - Feb 1, 2024).
January 10, 2024, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Rapid Micro Q4 rev ~$6.2-6.4M (+45%); FY rev ~$22.4-22.6M (+30%); cash $95M runway into H2 2026

Q4 revenue expected $6.2-6.4M (+45% YoY); FY23 revenue $22.4-22.6M (+30% YoY).
November 3, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01 ◈ Earnings Releases

Rapid Micro Biosystems Q3 revenue $6.1M (+30% YoY); reaffirms FY23 guidance at least $22M

Q3 revenue $6.1M, up 30% YoY; placed 5 Growth Direct systems, validated 4.
September 26, 2023, 7:59 PM ET other material materiality 0.70 positive item 8.01

Rapid Micro Biosystems regains Nasdaq minimum bid price compliance

Received Nasdaq deficiency notice on Sept 13 after bid price below $1 for 30 consecutive days (July 31-Sept 11).
September 19, 2023, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

Rapid Micro Biosystems receives Nasdaq delisting notice over bid price below $1.00

Received Nasdaq deficiency notice on Sept 13, 2023; bid price below $1.00 for 30 consecutive business days ending Sept 11, 2023.
August 4, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Q2 revenue $5.0M (+30% YoY); net loss $14.0M; reaffirms FY2023 guidance

Total revenue $5.0M, up 30% from $3.9M in Q2 2022; net loss $14.0M ($0.33 per share) vs $13.1M ($0.31).
May 5, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Rapid Micro Biosystems Q1 revenue $5.0M (+21% YoY); reaffirms FY23 guidance of at least $22.0M

Total revenue $5.0M, up 21% YoY; recurring revenue $3.3M (+22%).
March 3, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases ×3

Rapid Micro Biosystems Q4 commercial revenue $4.4M, FY2022 $17.1M; guides FY2023 at least $22M

Q4 2022 commercial revenue $4.4M (vs $4.9M prior year); net loss $16.4M ($0.39 per share).
December 1, 2022, 6:59 PM ET other material materiality 0.65 negative item 7.01 item 8.01 item 9.01

Rapid Micro Biosystems ends strategic review; no binding offers received for sale

Board concludes review of strategic alternatives that began August 2022; no parties submitted binding offers to acquire all outstanding shares.
November 10, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Rapid Micro Biosystems Q3 commercial revenue $4.7M, net loss $16.3M, reaffirms FY2022 guidance

Commercial revenue $4.7M (down 25% YoY from $6.3M); recurring revenue up 34% to $2.9M.
August 12, 2022, 7:59 PM ET earnings materiality 0.85 negative item 1.01 item 2.02 item 2.05 item 3.03 item 5.02 item 5.03 item 7.01 item 9.01 ◈ executive_change

Rapid Micro Biosystems Q2 revenue $3.9M; lowers FY22 outlook to ≥$17M, cuts 20% workforce

Q2 commercial revenue $3.9M vs $5.7M YoY; net loss $13.1M ($0.31 loss per share).
May 10, 2022, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01

Rapid Micro Biosystems Q1 commercial revenue $4.2M, down from $4.8M; reaffirms FY2022 revenue $27-32M

Commercial revenue $4.2M (Q1 2021: $4.8M, including $0.2M BARDA); recurring revenue up 66% to $2.7M.
January 10, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Rapid Micro Bio pre-announces Q4 rev $4.7-5.2M; FY22 outlook $27-32M

Preliminary Q4 total revenue $4.7M-$5.2M; commercial $4.5M-$4.9M; non-commercial (BARDA) $0.2M-$0.3M.
November 12, 2021, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Rapid Micro Biosystems Q3 commercial revenue $6.3M (+27%); reaffirms FY21 outlook

Commercial revenue $6.3M (+27% YoY); recurring commercial revenue $2.2M (+154% YoY).
September 23, 2021, 7:59 PM ET debt materiality 0.60 neutral item 1.02 item 9.01

Rapid Micro Biosystems pays $28.7M to terminate Kennedy Lewis loan, releases liens

Paid $28.7M to terminate Loan and Security Agreement with Kennedy Lewis Management LP.
August 26, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Rapid Micro Q2 commercial revenue $5.7M (+135% YoY); full-year outlook at least $24M

Q2 total revenue $6.1M vs $2.6M YoY; net loss ($11.8M) vs ($9.3M) YoY.